Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01434381|
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : February 11, 2014
- The malaria vaccine Pfs25-EPA/Alhydrogel may help block malaria parasites from developing in mosquitoes. When a mosquito bites a vaccinated person, the vaccine should prevent parasites from developing in the mosquito. As a result, the mosquito will not spread malaria to the next person it bites. However, the vaccine will not directly prevent people from getting sick with malaria. Researchers want to test the safety of and response to this vaccine.
- To test the safety of the malaria vaccine Pfs25-EPA/Alhydrogel.
- Healthy volunteers between 18 and 50 years of age.
- Participants will be screened with a medical history, physical exam, and blood tests.
- They will be assigned to a study group to have either two or three doses of the vaccine. Participants will have checkups after each dose of vaccine,
- The additional doses will be given 2 months or 2 and 4 months after the first vaccine.
- Participants will have regular blood tests to check the level of the response to the vaccine.
- They will be followed for up to 1 year after the last vaccine to have any additional tests as needed.
|Condition or disease||Intervention/treatment||Phase|
|Malaria||Biological: Pfs25-EPA/Alhydrogel||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open Label Phase 1 Study in Malaria Naive Adults of the Safety and Immunogenicity of Pfs25-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
- Incidence of local and systemic adverse events [ Time Frame: All adverse events will be recorded though Day 28 after each vaccination. The frequency of systemic and local AEs will be summarized. ]Subjects will be monitored for 30 minutes following each immunization. Subjects will return to the clinic on Days 3,7,14 and 28 following each vaccination for clinical assessments, and periodically thereafter until completion
- To determine the antibody response to the Pfs25 protein vaccines as measured by ELISA and transmission blocking assays, and the effect on antibody responses of a third dose at four months [ Time Frame: ELISA testing will occur on vaccination days, 2 weeks after each vaccination, and periodically until study completion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01434381
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Patrick Duffy, MD||National Institute of Allergy and Infectious Diseases (NIAID)|